TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17452166

Group type: EXPERIMENTAL
Intervention: Controlled-release paroxetine
Number of subjects: 14
Study: 15646732

Group type: EXPERIMENTAL
Intervention: Metoprolol treatment
Number of subjects: 0
Study: 11496277

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2650
Study: 9510396

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha) therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (14 patients)
Number of subjects: 100
Study: 7493145

Group type: COMPARATOR
Intervention: Fentanyl 0 micrograms (Group I)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl 7.5 micrograms (Group II)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms (Group III)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl 12.5 micrograms (Group IV)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms (Group V)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl 12.5 micrograms or 15 micrograms
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group IV & V
Number of subjects: 75
Study: 2132678

Group type: EXPERIMENTAL
Intervention: Target slide with greater number of pairings with shock in the first series
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Random sequence of slide-shock trials in the second series
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: On-line probability estimates and electrodermal responding
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Covariation bias
Number of subjects: 20
Study: 7357809

Group type: EXPERIMENTAL
Intervention: Nefopam 45 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nefopam 90 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propoxyphene 65 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31922998

Group type: EXPERIMENTAL
Intervention: KDIGO bundle compliance
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Nephrotoxic drugs discontinuation
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Volume optimization
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Functional hemodynamic monitoring
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Monitoring of serum creatinine and urine output
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Avoidance of hyperglycemia
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Use of radiocontrast agents
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Average supportive measures received
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Comparison of measures between AKI and non-AKI patients
Number of subjects: 95
Study: 31260943

Group type: EXPERIMENTAL
Intervention: APT + usual care
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 24
Study: 28329211

Group type: EXPERIMENTAL
Intervention: GEN‐003 (30 µg)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: GEN‐003 (100 µg)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: GEN‐003 (10 µg)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Antigens without adjuvant
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 25649717

Group type: EXPERIMENTAL
Intervention: SpHb Group (continuous noninvasive hemoglobin monitoring)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (intermittent blood sampling)
Number of subjects: 0
Study: 23343318

Group type: EXPERIMENTAL
Intervention: Professional-facilitated intervention (PFI; N=509)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Self-help (SH; N=326)
Number of subjects: 835
Study: 21209231

Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg/day (2 × 100 mg tablets)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19216606

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (0.2%)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution (2%)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (1%)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no chlorhexidine treatment)
Number of subjects: 44
Study: 17944273

Group type: EXPERIMENTAL
Intervention: Inhaled ribavirin
Number of subjects: 170000

Group type: EXPERIMENTAL
Intervention: Promising new agents
Number of subjects: 170000
Study: 15555479

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (9 months of support and 3 months of follow-up)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 314
Study: 11574372

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% with sufentanil 0.75 microg/mL and epinephrine 1.25 microg/mL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Racemic bupivacaine 0.125% with sufentanil 0.75 microg/mL and epinephrine 1.25 microg/mL
Number of subjects: 80
Study: 9634262

Group type: EXPERIMENTAL
Intervention: Steam-distilled garlic oil preparation (5 mg twice a day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7945742

Group type: EXPERIMENTAL
Intervention: Antidepressant medications with a placebo run-in period
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Antidepressant medications with a post-randomization placebo treatment cell
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 101
Study: 1968233

Group type: EXPERIMENTAL
Intervention: Idazoxan (alpha‐2‐adrenoceptor antagonist)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Idazoxan and naloxone combination
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Idazoxan alone
Number of subjects: 8
Study: 373439

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus gentamicin (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus amikacin (group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus netilmicin (group 3)
Number of subjects: 0
Study: 30811963

Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28011247

Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 15 µg BID
Number of subjects: 841

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 841
Study: 25880172

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control
Number of subjects: 307
Study: 23382470

Group type: EXPERIMENTAL
Intervention: Corticorelin acetate (CrA) 1 mg twice per day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Corticorelin acetate (CrA)
Number of subjects: 200
Study: 21269553

Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre alone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Epley's manoeuvre plus labyrinthine sedative
Number of subjects: 51
Study: 19167712

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg/d
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg/d
Number of subjects: 35
Study: 17210208

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment nerve block
Number of subjects: 55

Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 55
Study: 15502038

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mivacurium (MV group, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.1 mg/kg pancuronium (PC group, n = 10)
Number of subjects: 20
Study: 11522179

Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 RNA levels
Number of subjects: 102
Study: 10661294

Group type: EXPERIMENTAL
Intervention: Nutritional support with enriched food supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care without nutritional intervention
Number of subjects: 0
Study: 7945560

Group type: EXPERIMENTAL
Intervention: Artificial whole-body ultraviolet radiation (UVR) for 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study: 3673913

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 31835966

Group type: EXPERIMENTAL
Intervention: FINE program (smoking cessation support services provided by trained pharmacists)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 5
Study: 29813097

Group type: EXPERIMENTAL
Intervention: B‐vitamins alone (560 μg of 5‐methyl‐THF, 3 mg of vitamin B6 and 20 μg of vitamin B12)
Number of subjects: 2381

Group type: EXPERIMENTAL
Intervention: n‐3 fatty acids alone (600 mg of EPA and DHA in a 2:1 ratio)
Number of subjects: 2381

Group type: EXPERIMENTAL
Intervention: B‐vitamins and n‐3 fatty acids
Number of subjects: 2381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2381
Study: 27578110

Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil (2.4 g per day for 8 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25703424

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 24024327

Group type: EXPERIMENTAL
Intervention: 1200‐Kcal basic Chinese traditional diet (BTCD)
Number of subjects: 694

Group type: COMPARATOR
Intervention: 1200‐Kcal standard western diet
Number of subjects: 694
Study: 20384434

Group type: EXPERIMENTAL
Intervention: Full model (FM) including age, sex, body mass index (BMI), systolic and diastolic blood pressure, smoking status, and 38 SNPs.
Number of subjects: 485

Group type: COMPARATOR
Intervention: Reduced model (RM) without SNPs.
Number of subjects: 485
Study: 18544144

Group type: EXPERIMENTAL
Intervention: Supraclavicular brachial plexus block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Infraclavicular brachial plexus block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison of both approaches
Number of subjects: 80
Study: 16644505

Group type: EXPERIMENTAL
Intervention: Nivatvongs technique
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional local anaesthetic infiltration
Number of subjects: 112
Study: 16191241

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study: 10966542

Group type: EXPERIMENTAL
Intervention: 2-lead system
Number of subjects: 16

Group type: COMPARATOR
Intervention: 3-lead system
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 16
Study: 8792890

Group type: EXPERIMENTAL
Intervention: Lidocaine aerosol 500 mg (100 mg/ml; Xylocain aerosol, ASTRA, Sweden)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 30
Study: 1627204

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 631

Group type: COMPARATOR
Intervention: Miconazole 2% cream
Number of subjects: 631
Study: 6398021

Group type: EXPERIMENTAL
Intervention: Immunosuppressive drug therapy with plasmapheresis (PP)
Number of subjects: 0
Study: 30941124

Group type: EXPERIMENTAL
Intervention: T cell therapy targeting HLA‐A02 restricted HIV antigen epitopes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 30069604

Group type: EXPERIMENTAL
Intervention: Hot condition (34.9 ± 0.3 °C, 36.6 ± 6.2% RH)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Neutral condition (22.4 ± 0.1 °C, 40.4 ± 6.5% RH)
Number of subjects: 15
Study: 26971352

Group type: EXPERIMENTAL
Intervention: Universal adhesive/resin cement with selective enamel etching (SB+E)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Universal adhesive/resin cement without selective enamel etching (SB-E)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-adhesive resin cement (RelyX Unicem 2, RXU2)
Number of subjects: 50
Study: 24215388

Group type: EXPERIMENTAL
Intervention: Single incision laparoscopic cholecystectomy (SILC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3-port laparoscopic cholecystectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: 4-port laparoscopic cholecystectomy
Number of subjects: 90
Study: 22193561

Group type: EXPERIMENTAL
Intervention: Interferon β‐1b
Number of subjects: 0
Study: 19666685

Group type: EXPERIMENTAL
Intervention: Novel contour enhanced funnel plots
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression based adjustment method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intention to treat analysis
Number of subjects: 0
Study: 17568252

Group type: EXPERIMENTAL
Intervention: 4 weeks of daily 6x15 min ergometer training at submaximal intensity plus 1 h/week group exercise session followed by 5 months of home-based ergometer training of 30 min/day plus 1 h/week group exercise session
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 5 months of home-based exercise training of moderate frequency and duration
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 39
Study: 15878101

Group type: EXPERIMENTAL
Intervention: 8 Gy in 1 fraction (8/1)
Number of subjects: 272

Group type: COMPARATOR
Intervention: 20 Gy in 5 fractions (20/5)
Number of subjects: 272
Study: 12062596

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (vinblastine 5 mg/m(2) i.v. bolus weekly for the first 5 weeks, and cisplatin, 100 mg/m(2) i.v. on Days 1 and 29) followed by concurrent chemotherapy/radiotherapy (cisplatin 75 mg/m(2) i.v. on Days 50, 71, and 92) during thoracic radiotherapy (63 Gy in 34 fractions during 7 weeks starting on Day 50)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Concurrent chemotherapy and hyperfractionated radiotherapy starting on Day 1 with a total dose of 69.6 Gy in 58 fractions during 6 weeks, 1.2 Gy/fraction b.i.d. (cisplatin, 50 mg/m(2) i.v. on Days 1 and 8, and oral VP‐16, 50 mg b.i.d. for 10 days only on the days of thoracic radiotherapy repeated on Day 29)
Number of subjects: 163
Study: 9593141

Group type: EXPERIMENTAL
Intervention: sorivudine (40 mg once daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: acyclovir (800 mg five times daily)
Number of subjects: 170
Study: 8561655

Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids (DRCA) with avocado (30% of total calories as fat, 75% of total fat from avocado)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-saturated fat diet without avocado (DRSA)
Number of subjects: 16
Study: 2235803

Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with significant bacteriuria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional belief of alkalinizing urine
Number of subjects: 0
Study: 278688

Group type: EXPERIMENTAL
Intervention: Toothbrush with supervised oral cleaning
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Mefaka (chewing stick) with supervised oral cleaning
Number of subjects: 248

Group type: COMPARATOR
Intervention: Instruction only (Control)
Number of subjects: 248
Study: 31301476

Group type: EXPERIMENTAL
Intervention: Self-guided internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 190
Study: 28410767

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 91

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 91
Study: 26094635

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous microwave ablation with ethanol injection
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ultrasound-guided percutaneous microwave ablation without ethanol injection (control group)
Number of subjects: 49
Study: 23489301

Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5 and 25 mg daily)
Number of subjects: 4168

Group type: COMPARATOR
Intervention: Comparator therapies (other antidiabetic agents)
Number of subjects: 4168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4168
Study: 21732835

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7141
Study: 19114436

Group type: EXPERIMENTAL
Intervention: Occupational therapy for 12 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 44
Study: 17337647

Group type: EXPERIMENTAL
Intervention: Smoking cessation program attendance
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Age increase (1 SD = 2.45 years)
Number of subjects: 164
Study: 15569117

Group type: EXPERIMENTAL
Intervention: Anti-Saccharomyces cerevisiae mannan detected using the Lille assay
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Different assays for anti-Saccharomyces cerevisiae mannan detection
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Concordance of anti-Saccharomyces cerevisiae mannan detection
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Comparison of anti-Saccharomyces cerevisiae mannan in Crohn's disease vs. ulcerative colitis
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Correlation of anti-Saccharomyces cerevisiae mannan with clinical features
Number of subjects: 493
Study: 11416883

Group type: EXPERIMENTAL
Intervention: Intravenous BH4 (10 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9595286

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day for 16 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Spironolactone washout
Number of subjects: 9
Study: 7801667

Group type: EXPERIMENTAL
Intervention: molsidomine 8 mg bid
Number of subjects: 24
Study: 3050654

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg twice daily for 7 days
Number of subjects: 143

Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice daily for 7 days
Number of subjects: 143
Study: 30665513

Group type: EXPERIMENTAL
Intervention: Supervised ground-based walking training (30–45 min, 2–3 times weekly for 8–10 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Supervised ground-based walking training
Number of subjects: 78
Study: 28374089

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 25945012

Group type: EXPERIMENTAL
Intervention: PDN+MTD 500 mg three times daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PTX+MTD 500 mg three times daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: MTD
Number of subjects: 135
Study: 23438710

Group type: EXPERIMENTAL
Intervention: Television report about the adverse health effects of WiFi (n=76)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control film (n=71)
Number of subjects: 147
Study: 21285094

Group type: EXPERIMENTAL
Intervention: Collaborative model of depression care (problem-solving therapy, antidepressants, symptom monitoring, and relapse prevention)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Collaborative model of depression care (for patients with depression recurrence)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 472
Study: 19920418

Group type: EXPERIMENTAL
Intervention: Double-injection technique
Number of subjects: 92

Group type: COMPARATOR
Intervention: Single-injection technique
Number of subjects: 92
Study: 17899571

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (90 mg daily)
Number of subjects: 46
Study: 14645938

Group type: EXPERIMENTAL
Intervention: Tobacco control intervention in grocery stores
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control stores (no intervention)
Number of subjects: 7
Study: 12528731

Group type: EXPERIMENTAL
Intervention: Short form information
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Long form information
Number of subjects: 787
Study: 9372883

Group type: COMPARATOR
Intervention: Preoperative autologous blood donation (PAD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preoperative recombinant human erythropoietin (Epoetin alfa)
Number of subjects: 120
Study: 8264923

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3514833

Group type: EXPERIMENTAL
Intervention: Untreated own mother's milk
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pooled pasteurized preterm milk
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (750 IU daily from 2nd week of life)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bone-gla-protein
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reexamination of infants (4 to 11 months after birth)
Number of subjects: 36
Study: 29561245

Group type: EXPERIMENTAL
Intervention: Downhill running (n=10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Flat running (n=9)
Number of subjects: 19
Study: 25762401

Group type: EXPERIMENTAL
Intervention: Wound analgesia with bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with free-saline solution
Number of subjects: 60
Study: 23629583

Group type: EXPERIMENTAL
Intervention: Long Range (LR) resistance training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Short Range (SR) resistance training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Detraining effects on LR and SR groups
Number of subjects: 26
Study: 22541040

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Naltrexone and behavioral interventions
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Naltrexone and smoking reduction
Number of subjects: 1383
Study: 19798074

Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Diet plus Exercise (D+E)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 328